<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329003</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-11-YS-620-CTIL</org_study_id>
    <nct_id>NCT01329003</nct_id>
  </id_info>
  <brief_title>DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)</brief_title>
  <official_title>DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Silicosis is well-known occupational disease caused by free crystalline silica (silicon&#xD;
      dioxide) and is marked by inflammation and pulmonary fibrosis. There are cumulative evidences&#xD;
      that exposure to Caesar stone (quartz surface products that manufactured from up to 93%&#xD;
      quartz, polymer resins and pigments) is particularly dangerous to exposed workers.&#xD;
&#xD;
      Goals: To examine correlation between disease and exposure to Caesar stone and genetic&#xD;
      differences regarding genes involved in oxidative stress to understand Genetic susceptibility&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a sub-study of &quot;DNA-damage biomarkers to monitor and early detect health impairment in&#xD;
      workers exposed to Silica (Caesar Stone)&quot; study. Study participants would be recruited during&#xD;
      two years of the study. They will be asked to come to a single visit at Pulmonary Laboratory&#xD;
      of Tel Aviv Medical Center. During the meeting, participants will be given a precise&#xD;
      explanation about the tests they will perform and after signing the informed consent will&#xD;
      perform following tests:&#xD;
&#xD;
        1. Induced sputum (IS)&#xD;
&#xD;
        2. Exhaled Breath Condensate&#xD;
&#xD;
        3. Pulmonary function tests (PFTs)&#xD;
&#xD;
        4. Participants will be asked to complete occupational questionnaire&#xD;
&#xD;
      Genetic studies (DNA) will be done from peripheral blood samples (20 ml) to study differences&#xD;
      in Heme oxygenase 1 (HO-1) gene sequencing between participants with evidences of clinically&#xD;
      definite silicosis according to American Thoracic Society/European Respiratory Society&#xD;
      (ATS/ERS) guidelines and participants without evidences of clinically definite silicosis.DNA&#xD;
      samples will be obtained and coded in the same day of a participant visit and after&#xD;
      collecting reasonable amount of samples examination of genes of interest will be&#xD;
      done.Analysis of data will be done after the completion of data collection and laboratory&#xD;
      tests.&#xD;
&#xD;
      Each sample will be given specific code to protect confidentiality of participants. Blood&#xD;
      samples, test results and the code key will be kept in different places and only few research&#xD;
      staff will have the accessibility to genetic information. In any case employers or any other&#xD;
      persons that not included in research staff will not have any accessibility to this&#xD;
      information. In this study genetic analysis is not connected to gender, nationality or any&#xD;
      other social feature.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinically definite silicosis according to American Thoracic Society/European Respiratory Society (ATS/ERS)guidelines</measure>
    <time_frame>one day</time_frame>
    <description>Occupational physician examination&#xD;
Pulmonary function tests (PFTs): The measurement will be performed using standard protocols according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines. Including Lung diffusion testing&#xD;
Computed Tomography (CT) test if need</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Heme oxygenase 1 (HO-1) gene sequencing</measure>
    <time_frame>one day</time_frame>
    <description>Genetic studies (DNA) will be done from peripheral blood samples (20 ml) to study differences in Heme oxygenase 1 (HO-1) gene sequencing between participants with evidences of clinically definite silicosis according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines and participants without evidences of clinically definite silicosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Silicosis</condition>
  <arm_group>
    <arm_group_label>exposed workers</arm_group_label>
    <description>At least six months of occupational exposure to Caesar stone</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood 20 ml(cc)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        At least six months of occupational exposure to Caesar stone&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male&#xD;
&#xD;
          2. 18-70 years old&#xD;
&#xD;
          3. At least six months of professional exposure to Caesar stone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other occupational exposure (welding of any kind)&#xD;
&#xD;
          2. Chronic Obstructive Pulmonary Disease (COPD), tuberculosis, asthma, autoimmune disease&#xD;
             in healthy exposed workers&#xD;
&#xD;
          3. Interstitial lung disease in exposed workers with clinically approved silicosis&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehuda Shwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv medical center. Pulmonary and Allergy department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daria Bliznuk, BSc</last_name>
    <phone>972-0506353669</phone>
    <email>dasha_bl@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Fairman, professor</last_name>
    <phone>972-3-6973988</phone>
    <email>lizif@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pulmonary Laboratory of Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Daria Bliznuk, BSc</last_name>
      <phone>972-0506353669</phone>
      <email>dasha_bl@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Fierman, professor</last_name>
      <phone>972-3-6973988</phone>
      <email>lizif@tasmc.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Fierman, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yehuda Shwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mordehai Kremer, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daria Bliznuk, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Golov, Ms</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>February 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>April 1, 2011</last_update_submitted>
  <last_update_submitted_qc>April 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Elizabeth Fairman</name_title>
    <organization>Tel Aviv medical center</organization>
  </responsible_party>
  <keyword>Silicosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

